Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation

被引:115
|
作者
Thiel, Kristina W. [1 ]
Carpenter, Graham [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA
关键词
D O I
10.1073/pnas.0703854104
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Structural studies of the extracellular and tyrosine kinase domains of the epidermal growth factor receptor (ErbB-1) provide considerable insight into facets of the receptor activation mechanism, but the contributions of other regions of ErbB-1 have not been ascertained. This study demonstrates that the intracellular juxtamembrane (JM) region plays a vital role in the kinase activation mechanism. In the experiments described herein, the entire ErbB-1 intracellular domain (ICD) has been expressed in mammalian cells to explore the significance of the JM region in kinase activity. Deletion of the JM region (Delta JM) results in a severe loss of ICD tyrosine phosphorylation, indicating that this region is required for maximal activity of the tyrosine kinase domain. Coexpression of Delta JM and dimerization-deficient kinase domain ICD mutants revealed that the JM region is indispensable for allosteric kinase activation and productive monomer interactions within a dimer. Studies with the intact receptor confirmed the role of the JM region in kinase activation. Within the JM region, Thr-654 is a known protein kinase C (PKC) phosphorylation site that modulates kinase activity in the context of the intact ErbB-1 receptor; yet, the mechanism is not known. Whereas a T654A mutation promotes increased ICD tyrosine phosphorylation, the phosphomimetic T654D mutant generates a 50% reduction in ICD tyrosine phosphorylation. Similar to the Delta JM mutants, the T654D mutant ICD failed to interact with a wild-type monomer. This study reveals an integral role for the intracellular JM region of ErbB-1 in allosteric kinase activation.
引用
收藏
页码:19238 / 19243
页数:6
相关论文
共 50 条
  • [31] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Depression Reply
    Morgan, Jeffrey A.
    Quek, Richard
    George, Suzanne
    Block, Susan D.
    Demetri, George D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : E51 - E51
  • [32] Single residue mutagenesis of the EGF receptor juxtamembrane region defines an activation domain for tyrosine kinase activity
    Brewer, Monica Red
    Carpenter, Graham
    CANCER RESEARCH, 2009, 69
  • [33] Pharmacophore analysis of epidermal growth factor receptor tyrosine kinase inhibitors
    Peng, T
    Pei, JF
    Zhou, JJ
    ACTA CHIMICA SINICA, 2003, 61 (03) : 430 - 434
  • [34] Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy
    Raymond, E
    Faivre, S
    Armand, JP
    DRUGS, 2000, 60 (Suppl 1) : 15 - 23
  • [35] Evaluation of Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
    James M. Rae
    Marc E. Lippman
    Breast Cancer Research and Treatment, 2004, 83 : 99 - 107
  • [36] Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC
    Pallis, A. G.
    Syrigos, K. N.
    LUNG CANCER, 2013, 80 (02) : 120 - 130
  • [37] Salicylanilides as inhibitors of the protein tyrosine kinase epidermal growth factor receptor
    Liechti, C
    Séquin, U
    Bold, G
    Furet, P
    Meyer, T
    Traxler, P
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2004, 39 (01) : 11 - 26
  • [38] Thermal inactivation of the protein tyrosine kinase of the epidermal growth factor receptor
    Stein, RA
    Staros, JV
    BIOCHEMISTRY, 1996, 35 (09) : 2878 - 2884
  • [39] Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as Anticancer Agents
    Fortunato Ciardiello
    Drugs, 2000, 60 : 25 - 32
  • [40] CALMODULIN INHIBITS THE EPIDERMAL GROWTH-FACTOR RECEPTOR TYROSINE KINASE
    SANJOSE, E
    BENGURIA, A
    GELLER, P
    VILLALOBO, A
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1992, 267 (21) : 15237 - 15245